| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Anders Ettrup, Jens D Mikkelsen, Szabolcs Lehel, Jacob Madsen, Elsebet Ø Nielsen, Mikael Palner, Daniel B Timmermann, Dan Peters, Gitte M Knudse. 11C-NS14492 as a novel PET radioligand for imaging cerebral alpha7 nicotinic acetylcholine receptors: in vivo evaluation and drug occupancy measurements. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. vol 52. issue 9. 2011-11-02. PMID:21828113. |
small-molecule α(7) nicotinic acetylcholine receptor (α(7)nachr) agonists are currently validated for use as treatment for cognitive disturbances in schizophrenia and in alzheimer disease. |
2011-11-02 |
2023-08-12 |
Not clear |
| Raja Dey, Lin Che. In search of allosteric modulators of a7-nAChR by solvent density guided virtual screening. Journal of biomolecular structure & dynamics. vol 28. issue 5. 2011-10-14. PMID:21294583. |
the subtype of α7 nachr has been considered as a potenial therapeutic target for alzheimer's disease, schizophrenia and other neurological and psychiatric disorders. |
2011-10-14 |
2023-08-12 |
Not clear |
| Arquimedes Cheffer, Henning Ulric. Inhibition mechanism of rat α₃β₄ nicotinic acetylcholine receptor by the Alzheimer therapeutic tacrine. Biochemistry. vol 50. issue 11. 2011-06-23. PMID:21247200. |
using fast kinetic whole-cell recording, we have now studied effects of tacrine, an agent used clinically to treat alzheimer's disease, on currents elicited by activation of rat α(3)β(4) nachr heterologously expressed in kxα3β4r2 cells. |
2011-06-23 |
2023-08-12 |
rat |
| Hui Zhen Nie, Sha Shi, Ronald J Lukas, Wen Juan Zhao, Yong Ning Sun, Ming Yi. Activation of α7 nicotinic receptor affects APP processing by regulating secretase activity in SH-EP1-α7 nAChR-hAPP695 cells. Brain research. vol 1356. 2011-06-17. PMID:20708605. |
multiple lines of evidence have implicated that nicotinic acetylcholine receptor (nachr) may be an important therapeutic target for the treatment of alzheimer's disease (ad). |
2011-06-17 |
2023-08-12 |
human |
| Christos Stergiou, Paraskevi Zisimopoulou, Socrates J Tzarto. Expression of water-soluble, ligand-binding concatameric extracellular domains of the human neuronal nicotinic receptor alpha4 and beta2 subunits in the yeast Pichia pastoris: glycosylation is not required for ligand binding. The Journal of biological chemistry. vol 286. issue 11. 2011-05-16. PMID:21252231. |
this nachr subtype is responsible for addiction to nicotine and is thought to be implicated in alzheimer and parkinson diseases and therefore presents an important target for drug design. |
2011-05-16 |
2023-08-12 |
human |
| Andreas Söderman, Jens D Mikkelsen, Mark J West, Ditte Z Christensen, Morten S Jense. Activation of nicotinic α(7) acetylcholine receptor enhances long term potentation in wild type mice but not in APP(swe)/PS1ΔE9 mice. Neuroscience letters. vol 487. issue 3. 2011-04-21. PMID:20974225. |
amyloid β (aβ) plays a central role in alzheimer's disease (ad) and binds to the nicotinic α(7) receptor (α(7) nachr). |
2011-04-21 |
2023-08-12 |
mouse |
| Theo Dinklo, Hamdy Shaban, Jan Willem Thuring, Hilde Lavreysen, Karen E Stevens, Lijun Zheng, Claire Mackie, Christopher Grantham, Ine Vandenberk, Greet Meulders, Luc Peeters, Hanne Verachtert, Erik De Prins, Anne S J Lesag. Characterization of 2-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-4-(4-pyridinyl)-5-thiazolemethanol (JNJ-1930942), a novel positive allosteric modulator of the {alpha}7 nicotinic acetylcholine receptor. The Journal of pharmacology and experimental therapeutics. vol 336. issue 2. 2011-03-03. PMID:21084390. |
the α(7) nicotinic acetylcholine receptor (nachr) is a potential therapeutic target for the treatment of cognitive deficits associated with schizophrenia, alzheimer's disease, parkinson's disease, and attention-deficit/hyperactivity disorder. |
2011-03-03 |
2023-08-12 |
mouse |
| H Jiang, C X Liu, J B Feng, P Wang, C P Zhao, Z H Xie, Y Wang, S L Xu, C Y Zheng, J Z B. Granulocyte colony-stimulating factor attenuates chronic neuroinflammation in the brain of amyloid precursor protein transgenic mice: an Alzheimer's disease mouse model. The Journal of international medical research. vol 38. issue 4. 2010-12-10. PMID:20926003. |
this study was designed to investigate whether g-csf could inhibit inflammation in a mouse model of alzheimer's disease through an α7 nicotinic acetylcholine receptor (α7 nachr) pathway. |
2010-12-10 |
2023-08-12 |
mouse |
| H Jiang, C X Liu, J B Feng, P Wang, C P Zhao, Z H Xie, Y Wang, S L Xu, C Y Zheng, J Z B. Granulocyte colony-stimulating factor attenuates chronic neuroinflammation in the brain of amyloid precursor protein transgenic mice: an Alzheimer's disease mouse model. The Journal of international medical research. vol 38. issue 4. 2010-12-10. PMID:20926003. |
it is concluded that g-csf might attenuate inflammation by down-regulating nf-κb and up-regulating α7 nachr in the brain of app transgenic mice, indicating a potential new therapeutic approach to alzheimer's disease. |
2010-12-10 |
2023-08-12 |
mouse |
| Ditte Z Christensen, Jens D Mikkelsen, Henrik H Hansen, Morten S Thomse. Repeated administration of alpha7 nicotinic acetylcholine receptor (nAChR) agonists, but not positive allosteric modulators, increases alpha7 nAChR levels in the brain. Journal of neurochemistry. vol 114. issue 4. 2010-10-06. PMID:20533993. |
the alpha7 nicotinic acetylcholine receptor (nachr) is an important target for treatment of cognitive deficits in schizophrenia and alzheimer's disease. |
2010-10-06 |
2023-08-12 |
rat |
| R Scott Bitner, William H Bunnelle, Michael W Decker, Karla U Drescher, Kathy L Kohlhaas, Stella Markosyan, Kennan C Marsh, Arthur L Nikkel, Kaitlin Browman, Rich Radek, David J Anderson, Jerry Buccafusco, Murali Gopalakrishna. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease. The Journal of pharmacology and experimental therapeutics. vol 334. issue 3. 2010-09-23. PMID:20504913. |
we previously reported that alpha7 nicotinic acetylcholine receptor (nachr) agonism produces efficacy in preclinical cognition models correlating with activation of cognitive and neuroprotective signaling pathways associated with alzheimer's disease (ad) pathology. |
2010-09-23 |
2023-08-12 |
mouse |
| John Malysz, David J Anderson, Jens H Grønlien, Jianguo Ji, William H Bunnelle, Monika Håkerud, Kirten Thorin-Hagene, Hilde Ween, Rosalind Helfrich, Min Hu, Earl Gubbins, Sujatha Gopalakrishnan, Pamela S Puttfarcken, Clark A Briggs, Jinhe Li, Michael D Meyer, Tino Dyhring, Philip K Ahring, Elsebet Ø Nielsen, Dan Peters, Daniel B Timmermann, Murali Gopalakrishna. In vitro pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107. The Journal of pharmacology and experimental therapeutics. vol 334. issue 3. 2010-09-23. PMID:20504915. |
enhancement of alpha7 nicotinic acetylcholine receptor (nachr) activity is considered a therapeutic approach for ameliorating cognitive deficits present in alzheimer's disease and schizophrenia. |
2010-09-23 |
2023-08-12 |
human |
| Xiao-Lan Qi, Zhi-Zhong Gua. [Neuroprotective effects of alpha7 neuronal acetylcholine receptor and its roles in the pathogenesis of Alzheimer's disease]. Zhonghua bing li xue za zhi = Chinese journal of pathology. vol 37. issue 1. 2010-09-13. PMID:18509986. |
to investigate the neuroprotective function of alpha7 nicotinic receptor (nachr) and its roles in the pathogenesis of alzheimer's disease (ad). |
2010-09-13 |
2023-08-12 |
Not clear |
| Simon N Haydar, John Dunlo. Neuronal nicotinic acetylcholine receptors - targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer's disease. Current topics in medicinal chemistry. vol 10. issue 2. 2010-09-02. PMID:20166959. |
nicotinic acetylcholine receptors (nachr) have been strongly implicated as therapeutic targets for treating cognitive deficits in disorders such as schizophrenia and alzheimer's disease (ad). |
2010-09-02 |
2023-08-12 |
Not clear |
| Simon N Haydar, John Dunlo. Neuronal nicotinic acetylcholine receptors - targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer's disease. Current topics in medicinal chemistry. vol 10. issue 2. 2010-09-02. PMID:20166959. |
in particular alpha7 and alpha4beta2 subtype-selective nachr agonists and partial agonists have been developed as potential candidates for the treatment of schizophrenia, cognitive disorders (including alzheimer's disease), and inflammation. |
2010-09-02 |
2023-08-12 |
Not clear |
| Chiara Ghiron, Simon N Haydar, Suzan Aschmies, Hendrick Bothmann, Cristiana Castaldo, Giuseppe Cocconcelli, Thomas A Comery, Li Di, John Dunlop, Tim Lock, Angela Kramer, Dianne Kowal, Flora Jow, Steve Grauer, Boyd Harrison, Salvatore La Rosa, Laura Maccari, Karen L Marquis, Iolanda Micco, Arianna Nencini, Joanna Quinn, Albert J Robichaud, Renza Roncarati, Carla Scali, Georg C Terstappen, Elisa Turlizzi, Michela Valacchi, Maurizio Varrone, Riccardo Zanaletti, Ugo Zanell. Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914). Journal of medicinal chemistry. vol 53. issue 11. 2010-07-01. PMID:20465311. |
we report a series of novel, potent small molecule agonists (4-18) of the alpha7 nachr deriving from our continuing efforts in the areas of alzheimer's disease and schizophrenia. |
2010-07-01 |
2023-08-12 |
Not clear |
| Andrew G Horti, Yongjun Gao, Hiroto Kuwabara, Robert F Dannal. Development of radioligands with optimized imaging properties for quantification of nicotinic acetylcholine receptors by positron emission tomography. Life sciences. vol 86. issue 15-16. 2010-04-15. PMID:19303028. |
there is an urgent need for positron emission tomography (pet) imaging of the nicotinic acetylcholine receptors (nachr) to study the role of the nicotinic system in alzheimer's and parkinson's diseases, schizophrenia, drug dependence and many other disorders. |
2010-04-15 |
2023-08-12 |
Not clear |
| Morten S Thomsen, Henrik H Hansen, Daniel B Timmerman, Jens D Mikkelse. Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Current pharmaceutical design. vol 16. issue 3. 2010-04-02. PMID:20109142. |
agonists and positive allosteric modulators of the alpha(7) nicotinic acetylcholine receptor (nachr) are currently being developed for the treatment of cognitive disturbances in patients with schizophrenia or alzheimer's disease. |
2010-04-02 |
2023-08-12 |
human |
| Morten S Thomsen, Henrik H Hansen, Daniel B Timmerman, Jens D Mikkelse. Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Current pharmaceutical design. vol 16. issue 3. 2010-04-02. PMID:20109142. |
accordingly, systemic administration of alpha(7) nachr agonists improves learning, memory, and attentional function in variety of animal models, and pro-cognitive effects of alpha(7) nachr agonists have recently been demonstrated in patients with schizophrenia or alzheimer's disease. |
2010-04-02 |
2023-08-12 |
human |
| Caterina M Hernandez, Rakez Kayed, Hui Zheng, J David Sweatt, Kelly T Dinele. Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 30. issue 7. 2010-03-19. PMID:20164328. |
early alzheimer's disease (ad) is marked by cholinergic hypofunction, neuronal marker loss, and decreased nicotinic acetylcholine receptor (nachr) density from the cortex and hippocampus. |
2010-03-19 |
2023-08-12 |
mouse |